Heart Hope: Announcing the Encouraging Results of a Cell-Therapy Clinical Study by LongeveronBenzinga • 09/15/21
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmBusiness Wire • 09/15/21
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmBusiness Wire • 09/14/21
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Longeveron Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – LGVNBusiness Wire • 09/14/21
Pomerantz Law Firm Announces the Filing of a Class Action Against Longeveron Inc. and Certain Officers - LGVNPRNewsWire • 09/14/21
Longeveron Partners with Kinesiometrics to Create and Implement Cutting-Edge Smart Phone App to Measure Physical Responses to Cell TherapyGlobeNewsWire • 09/13/21
Longeveron Announces Final Results of Phase 1 Clinical Study of Lomecel-B Injection in Hypoplastic Left Heart Syndrome PatientsBenzinga • 09/09/21
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Longeveron Inc. - LGVNNewsfile Corp • 08/17/21
Longeveron's (LGVN) CEO Geoff Green on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/14/21
Longeveron Spikes As Lead Drug Produces Dose-Dependent Response In Aging Frailty Study; Primary Endpoint Not MetBenzinga • 08/13/21
Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2021 Financial ResultsGlobeNewsWire • 08/13/21
Longeveron Announces Topline Results of Phase 2b Study of Lomecel-B for Aging FrailtyGlobeNewsWire • 08/13/21
Longeveron to Release Second Quarter 2021 Financial Results and Hold Conference Call on August 13, 2021GlobeNewsWire • 08/10/21
Longeveron's Founders Hopeful That With Continued Clinical Trial Success, Lomecel-B May Win Regulatory ApprovalBenzinga • 07/07/21
Longeveron Announces Two Abstracts Accepted for Presentation at the Gerontological Society of America 2021 Annual Scientific MeetingGlobeNewsWire • 06/30/21
Longeveron, Armed with Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer's Disease, Presenting at AAIC & Headed to Phase 2 TrialsBenzinga • 06/28/21
Longeveron Announces Abstract Highlighting Data from Phase 1 Alzheimer's Disease Trial Accepted for Developing Topics Presentation at the 2021 Annual Alzheimer's Association International ConferenceBenzinga • 06/24/21
Longeveron Announces the Appointment of Ursula Ungaro to its Board of DirectorsGlobeNewsWire • 05/25/21
Longeveron Announces the Hiring of Dan Gincel, Ph.D., as Senior Vice President, Strategic Collaborations & Scientific AffairsGlobeNewsWire • 05/18/21
Longeveron's (LGVN) CEO Geoff Green on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/14/21
Longeveron Inc. Provides Corporate Update and Reports First Quarter 2021 Financial ResultsGlobeNewsWire • 05/14/21